Excipient Compatibility Study

It is an early screen that ranks excipients. It does not set shelf life; that comes from stability data on the finished product at the long-term condition your market needs.

ICH Q8(R2), the International Council for Harmonisation guideline on pharmaceutical development, states that the compatibility of the drug substance with the excipients "should be evaluated". It also says excipient-to-excipient compatibility should be established where relevant, for example in a dual preservative system. The guideline says "should", not "mandatory".

Lactose is the usual first suspect for amine-containing drugs, because amines can react with reducing sugars in the Maillard reaction.

Forced degradation stresses the API alone to map how it breaks down. A compatibility study asks whether an excipient changes that behavior. A stability study follows the finished product across its shelf life. Preformulation is the early development stage where the first two are done.

Four choices decide it: the drug-to-excipient ratio, a drug-only control, the storage conditions and time points, and whether degradation is measured by HPLC.

Four design choices behind a trustworthy study

• Ratio. A 1:1 weight ratio is a common screening choice, as in the levothyroxine study. FDA assessors check the ratio of excipient to API per formula. A sound approach is to screen at 1:1, then repeat the lead candidates at the formula ratio, because a lubricant present as a small fraction of a blend meets the API very differently than at 1:1.
• Control. Store a drug-only control with every arm. Without it, degradation cannot be assigned to the excipient.
• Conditions. 40°C and 75% relative humidity (RH) is the conventional accelerated condition; the conventional studies in a 2023 paper in AAPS (American Association of Pharmaceutical Scientists) PharmSciTech ran it for 3 to 6 months. A screening design can use open and closed vials at 40°C/75% RH plus a closed 25°C/60% RH comparator, pulled at 2, 4 and 8 weeks.
• Speed. In that paper, a 60°C vial-in-vial method run for 1 to 2 weeks produced similar or higher degradation than the 3-to-6-month studies and kept the rank order, across 32 marketed formulations of six oral drugs. It is one study, so use it to rank excipients, not to clear them.

A sound report has a drug-only control, a stated ratio, an HPLC readout, stated conditions, recorded excipient grade and lot, and a conclusion backed by HPLC or finished-product data. The table sets a pass and a fail for each.

The last row matters because the olmesartan study found MCC shifted thermal stability by more than 100°C for olmesartan and lowered it by about 20°C for hydrochlorothiazide. Dissolution and long-term stability at 30°C/75% RH for 24 months showed no effect on product performance, so the authors did not treat it as an incompatibility. A report that also tracks degradants such as nitrosamine impurities against intake limits is stronger still.

For eight excipients, three storage arms and three pull points, plan about 9 g of API (90 vials at 100 mg each, in this model). The formula is vials × API per vial.

Vials = (excipients × arms × stored time points) + excipients (initial) + [control: arms × stored time points + 1].

Qualified B2B buyers can request evaluation quantities from us. Sample quantity, pricing and documentation are confirmed product by product, and available documentation may include a certificate of analysis (COA), specifications and SDS/MSDS (safety data sheets) where applicable. Pricing is quoted per product on request.

We are a Haridwar-based, technology-driven contract development and manufacturing organization (CDMO) for oral dosage forms, from product development through commercial manufacturing. We also supply steroid, peptide, hormone, general pharmaceutical and supplement APIs to business buyers. Use the sizing above to state the quantity you need, and see our API quality testing methods (HPLC, IR, mass spectrometry). When a formulation moves between sites, we recommend the compatibility report travels in the technology transfer handover.

To request an evaluation quantity, send the API name or CAS (Chemical Abstracts Service) number, quantity, specification or grade, destination country and company details through our contact form, by WhatsApp at +91 9899783330, or to sunil@aarisepharma.com.